CellaVision AB
F:C26
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CellaVision AB
F:C26
|
SE |
|
H
|
Hang Lung Properties Ltd
SWB:AOP
|
HK |
|
S2Medical AB (publ)
F:S21
|
SE |
|
Knights Group Holdings PLC
F:77Q
|
UK |
|
M
|
Mito Securities Co Ltd
F:896
|
JP |
Wall St Price Targets
C26 Price Targets Summary
CellaVision AB
According to Wall Street analysts, the average 1-year price target for C26 is 21.45 EUR with a low forecast of 20.83 EUR and a high forecast of 22.5 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is C26's stock price target?
Price Target
21.45
EUR
According to Wall Street analysts, the average 1-year price target for C26 is 21.45 EUR with a low forecast of 20.83 EUR and a high forecast of 22.5 EUR.
What is the Revenue forecast for CellaVision AB?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 12%. The projected CAGR for the next 3 years is 8%.
What is the Gross Profit forecast for CellaVision AB?
Projected CAGR
12%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 13%. The projected CAGR for the next 3 years is 12%.
What is the Operating Income forecast for CellaVision AB?
Projected CAGR
9%
Over the last 13 years, the compound annual growth rate for Operating Income has been 19%. The projected CAGR for the next 3 years is 9%.
What is the Pre-Tax Income forecast for CellaVision AB?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 20%. The projected CAGR for the next 3 years is 18%.
What is the Net Income forecast for CellaVision AB?
Projected CAGR
18%
Over the last 13 years, the compound annual growth rate for Net Income has been 28%. The projected CAGR for the next 3 years is 18%.
